/MNPR
MNPR Stock - Monopar Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$68.63+4.00%
+$2.64 (+4.00%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+62.8%upside
Target: $111.73
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MNPR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$67.94 – $69.32
TARGET (TP)$111.75
STOP LOSS$63.14
RISK/REWARD1:7.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.47
52W High$105.00
52W Low$21.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-16,161,721 | $-8,831,235 | $-10,536,877 | $-9,127,248 | $-6,508,875 |
| Net Income | $-15,586,419 | $-8,402,196 | $-10,515,638 | $-9,103,224 | $-6,304,573 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.36 | $-0.58 | $-0.83 | $-0.73 | $-0.58 |
Company Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Visit WebsiteRating Distribution
Strong Buy
1
13%
Buy / Outperform
7
88%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$81
Average Target
↑ 17.4% Upside
Now
$50
Low
$81
Average
$125
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2025 | Raymond James | Downgrade | Outperform | - |
| November 10th 2025 | Leerink Partners | Initiation | Outperform | $115 |
| October 13th 2025 | Barclays | Initiation | Overweight | $125 |
| September 9th 2025 | BTIG Research | Initiation | Buy | $87 |
| September 3rd 2025 | Oppenheimer | Initiation | Outperform | $77 |
| September 3rd 2025 | Raymond James | Initiation | Strong Buy | $80 |
| August 26th 2025 | H.C. Wainwright | Resumed | Buy | $70 |
| July 7th 2025 | Cantor Fitzgerald | Initiation | Overweight | $74 |
| June 23rd 2025 | Chardan Capital Markets | Initiation | Buy | $60 |
| March 19th 2025 | Piper Sandler | Resumed | Overweight | $76 |
| January 10th 2025 | Piper Sandler | Initiation | Overweight | $72 |
| October 11th 2024 | Rodman & Renshaw | Initiation | Buy | $50 |
Earnings History & Surprises
MNPRBeat Rate
68%
Last 19 quarters
Avg Surprise
-13.8%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$-0.48
Q4 2025
EPS Surprise History
Q1 24
+29.4%
$-0.60vs$-0.85
Q2 24
+41.2%
$-0.50vs$-0.85
Q3 24
-11.1%
$-0.50vs$-0.45
Q4 24
+19.6%
$-0.37vs$-0.46
Q1 25
-519.4%
$-2.23vs$-0.36
Q2 25
+41.5%
$-0.38vs$-0.65
Q3 25
+25.5%
$-0.35vs$-0.47
Q4 25
-4.3%
$-0.48vs$-0.46
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.55 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.46 | $-0.48 | -4.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.47 | $-0.35 | +25.5% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.65 | $-0.38 | +41.5% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.36 | $-2.23 | -519.4% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-0.46 | $-0.37 | +19.6% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.45 | $-0.50 | -11.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.85 | $-0.50 | +41.2% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.85 | $-0.60 | +29.4% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.95 | $-0.70 | +26.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.95 | $-0.80 | +15.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.00 | $-0.95 | +5.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-1.05 | $-1.10 | -4.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1.15 | $-0.95 | +17.4% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.05 | $-1.10 | -4.8% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.20 | $-0.95 | +20.8% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-0.90 | $-1.05 | -16.7% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-1.10 | $-1.00 | +9.1% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-1.05 | $-0.85 | +19.0% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-1.10 | $-0.80 | +27.3% | ✓ BEAT |
Latest News
Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123
➖ NeutralBenzinga•Nov 14, 2025, 11:54 AM
Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 09:15 PM
Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 01:06 PM
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100
📈 PositiveBenzinga•Nov 10, 2025, 12:19 PM
Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $115
📈 PositiveBenzinga•Nov 10, 2025, 11:59 AM
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
📈 PositiveBenzinga•Oct 13, 2025, 12:05 PM•Also:
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142
📈 PositiveBenzinga•Oct 6, 2025, 04:59 PM
Monopar Therapeutics shares are trading higher after Oppenheimer raised its price target on the stock from $77 to $115.
📈 PositiveBenzinga•Oct 2, 2025, 02:10 PM
Oppenheimer Maintains Outperform on Monopar Therapeutics, Raises Price Target to $115
📈 PositiveBenzinga•Oct 2, 2025, 01:31 PM
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105
📈 PositiveBenzinga•Sep 29, 2025, 02:09 PM
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95
📈 PositiveBenzinga•Sep 25, 2025, 04:52 PM
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104
📈 PositiveBenzinga•Sep 25, 2025, 11:56 AM
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85
📈 PositiveBenzinga•Sep 25, 2025, 11:52 AM
Reported Earlier, Monopar Therapeutics Prices $135M Underwritten Offering Of 1,034,433 Common Stock And Pre-Funded Warrants At $67.67 Per Share; Plans $35M Buyback Of Shares From Tactic Pharma
➖ NeutralBenzinga•Sep 24, 2025, 06:25 AM
Lake Street Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $106
📈 PositiveBenzinga•Sep 23, 2025, 02:38 PM
Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $60 Price Target
📈 PositiveBenzinga•Sep 16, 2025, 11:11 AM
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $87 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 02:41 PM
Monopar To Present 6-Year Data Showing Sustained Neurological Improvement With ALXN1840 in Wilson Disease On UWDRS Part II and III At ANA Annual Meeting
📈 PositiveBenzinga•Sep 14, 2025, 12:15 PM
BTIG Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $87
📈 PositiveBenzinga•Sep 9, 2025, 10:50 AM
Raymond James Initiates Coverage On Monopar Therapeutics with Strong Buy Rating, Announces Price Target of $80
📈 PositiveBenzinga•Sep 3, 2025, 04:49 PM
Frequently Asked Questions about MNPR
What is MNPR's current stock price?
Monopar Therapeutics Inc. (MNPR) is currently trading at $68.63 per share. The stock has moved +4.00% today.
What is the analyst price target for MNPR?
The average analyst price target for MNPR is $111.75, based on 1 analyst.
What sector is Monopar Therapeutics Inc. in?
Monopar Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MNPR's market cap?
Monopar Therapeutics Inc. has a market capitalization of $0.46 billion, making it a small-cap company.
Does MNPR pay dividends?
No, Monopar Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKBA
Akebia Therapeutics, Inc.
$1.66
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
CMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
LXRX
Lexicon Pharmaceuticals, Inc.
$1.17
Mkt Cap: $0.4B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
Explore stocks similar to MNPR for comparison